Connect with us

Health

US Pauses Chikungunya Vaccine Over Severe Side Effects

Published

on

837 Views

US health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of “serious adverse events”, the drug’s French maker said Monday.

Ixchiq is one of just two vaccines approved by the US Food and Drug Administration for the mosquito-spread virus, which mainly occurs in tropical and subtropical regions but has recently been discovered to countries worldwide.

French company Valneva obtained US approval for the vaccine in 2023, but reports of side effects have prompted reviews in particular over its use in older patients, including by the European Medicines Agency this year.

“The suspension of the license is effective immediately,” Valneva said of the FDA order issued Friday, citing four additional cases of serious side effects, three of which involved people aged 70 to 82.

“As we determine potential next steps, and as the clear threat of chikungunya continues to escalate globally, Valneva remains fully committed to maintaining access to our vaccine as a global health tool,” chief executive Thomas Lingelbach said in a statement.

Public health experts say chikungunya could be a potential future pandemic threat as climate change pushes the mosquitoes that spread it into new regions.

The symptoms are similar to those of dengue fever and Zika virus, with high fever and severe joint pain that is often debilitating and varies in duration.

Chikungunya is rarely fatal, though there is an increased risk of death for babies and the elderly.

In July, the World Health Organization warned of the risks of a major chikungunya epidemic, calling for urgent action.

The agency said it was picking up the same early warning signs as in a major outbreak two decades ago, which swept across the Indian Ocean before spreading globally and affecting almost half a million people.

So far this year, Europe has seen 27 chikungunya outbreaks, a new record for the continent, the European Centre for Disease Prevention and Control said this month.

AFP

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Bayer to establish reproductive health commodities plant in Nigeria

The plant is expected to manufacture family planning commodities locally, reducing Nigeria’s dependence on imported products, creating jobs and contributing to economic growth.

Published

on

By

15 Views

•The Minister of Health and Social Welfare, Prof. Muhammad Pate

Global pharmaceutical company, Bayer, is to establish a reproductive health commodities manufacturing plant in Nigeria, with the facility currently under construction in Anambra State.

The plant is expected to manufacture family planning commodities locally, reducing Nigeria’s dependence on imported products, creating jobs and contributing to economic growth.

The Minister of Health and Social Welfare, Prof. Muhammad Pate, disclosed this in Abuja at the inauguration of the High-Level Inter-Ministerial Platform (IMP) on Family Planning, Health, Human Capital and Sustainable National Development.

Pate described the investment as evidence that President Bola Tinubu’s Executive Order on the pharmaceutical sector was beginning to attract significant investments in local pharmaceutical manufacturing, diagnostics and health technology.

Also speaking, the Managing Director of FP2030 West and Central Africa Office, Dr Alain Damiba, described the initiative as a major step towards strengthening cross-sector collaboration to improve health outcomes and accelerate Nigeria’s socio-economic development.

Damiba commended the Federal Government for adopting a whole-of-government approach, noting that the new platform demonstrated that health and family planning were national development priorities and not issues that should be left to the health sector alone.

“Health, including family planning, is a smart investment in human capital and Nigeria’s future,” Damiba said.

Source: The Guardian Nigeria

Continue Reading

Health

Medical Oxygen Killing More Than 600,000 Nigerians Annually

The project started its first phase by carrying out intervention work in three industrial areas of the state: quarry industrial site in Onueke, rice mill in Abakaliki, and timber market

Published

on

By

47 Views

•Professor Jesse Uneke

The Vice Chancellor of David Umahi Federal University of Health Sciences (DUFUS), Ebonyi State, Professor Jesse Uneke, has estimated that more than 600,000 Nigerians died yearly due to issues relating to the administration of medical oxygen.

Uneke, who is the Nigerian and State Lead/Principal Investigator for the EQUI-RESP Africa Research Project, disclosed this in Abakaliki, during the First Stakeholders’ Engagement Event/Co-Creation Workshop on Medical Oxygen Economy organised by the university in conjunction with the University of Edinburgh, UK, supported by the National Institute for Health and Research (NIHR), UK.

He explained that the administration of medical oxygen issues was happening because there was no platform where stakeholders in the medical oxygen space could come together to discuss the research-policy interface and see how to contextualise some of the strategies against the problems for the country.

“That is why, in this phase of this project, we have decided to start with this kind of stakeholders’ engagement. I am excited that we have every key stakeholder in the medical oxygen space represented here,” Uneke said.

He opined that the project started its first phase by carrying out intervention work in three industrial areas of the state: quarry industrial site in Onueke, rice mill in Abakaliki, and timber market.

This project has to do with respiratory health, and the idea is to come up with strategies that will lead to interventions that will improve health outcomes as far as respiratory health is concerned.

Continue Reading

Health

Pharmacists body say 9,850 professionals “Japa” in 5 years

He attributed the development to poor remuneration, weak workforce development plans and the failure to fully enforce the National Drug Distribution Guidelines introduced in 2015.

Published

on

By

89 Views

9,850 professional Nigerian pharmacists moved to countries like Canada, the UK, Australia and, to a much lesser extent, the USA and some Asian territories, in the last five years in search of better paychecks.

This was disclosed by the Association of Community Pharmacists of Nigeria, (ACPN) during their 45th Annual National Scientific Conference at the Bola Ahmed Tinubu International Scientific Conference Centre in Abuja.

The National Chairman of the association, Ambrose Ezeh, described the trend as a major threat to Nigeria’s healthcare system and pharmaceutical industry.

Ezeh said that records at the Pharmaceutical Society of Nigeria, PSN, National Secretariat showed that about 9,000 pharmacists exited Nigeria in the four and a half years preceding December 2026, while over 850 more obtained letters of good standing from the Pharmacists Council of Nigeria, PCN, in the first six months of 2026 alone.

He attributed the development to poor remuneration, weak workforce development plans and the failure to fully enforce the National Drug Distribution Guidelines introduced in 2015.

Continue Reading

Trending